IL325099A - Oral solid estrogen receptor antagonist dosage forms - Google Patents

Oral solid estrogen receptor antagonist dosage forms

Info

Publication number
IL325099A
IL325099A IL325099A IL32509925A IL325099A IL 325099 A IL325099 A IL 325099A IL 325099 A IL325099 A IL 325099A IL 32509925 A IL32509925 A IL 32509925A IL 325099 A IL325099 A IL 325099A
Authority
IL
Israel
Prior art keywords
compound
tablet
dosage form
oral dosage
polyethylene glycol
Prior art date
Application number
IL325099A
Other languages
English (en)
Hebrew (he)
Inventor
Iii Royal J Haskell
Joseph P Reo
Original Assignee
Arvinas Operations Inc
Iii Royal J Haskell
Joseph P Reo
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Arvinas Operations Inc, Iii Royal J Haskell, Joseph P Reo filed Critical Arvinas Operations Inc
Publication of IL325099A publication Critical patent/IL325099A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
IL325099A 2023-06-12 2024-06-11 Oral solid estrogen receptor antagonist dosage forms IL325099A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202363472523P 2023-06-12 2023-06-12
PCT/US2024/033417 WO2024258856A1 (fr) 2023-06-12 2024-06-11 Formes posologiques orales solides d'agents de dégradation des récepteurs des œstrogènes

Publications (1)

Publication Number Publication Date
IL325099A true IL325099A (en) 2026-02-01

Family

ID=91738206

Family Applications (1)

Application Number Title Priority Date Filing Date
IL325099A IL325099A (en) 2023-06-12 2024-06-11 Oral solid estrogen receptor antagonist dosage forms

Country Status (9)

Country Link
EP (1) EP4724045A1 (fr)
JP (1) JP2026522318A (fr)
KR (1) KR20260022394A (fr)
CN (1) CN121311218A (fr)
AU (1) AU2024303588A1 (fr)
IL (1) IL325099A (fr)
MX (1) MX2025014795A (fr)
TW (1) TW202500155A (fr)
WO (1) WO2024258856A1 (fr)

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9518953D0 (en) 1995-09-15 1995-11-15 Pfizer Ltd Pharmaceutical formulations
AU2010223105B2 (en) 2009-03-09 2016-05-12 Spi Pharma, Inc. Highly compactable and durable direct compression excipients and excipient systems
MX376083B (es) * 2015-06-04 2025-03-07 Pfizer Formas de dosificacion solidas de palbociclib.
IL266842B (en) 2016-12-01 2022-09-01 Arvinas Operations Inc History of tetrahydronaphthalene and tetrahydroisoquinoline as estrogen receptor antagonists
WO2021041348A1 (fr) 2019-08-26 2021-03-04 Arvinas Operations, Inc. Procédés de traitement du cancer du sein avec des dérivés de tétrahydronaphtalène en tant qu'agents de dégradation du récepteur des œstrogènes
AU2021342287A1 (en) * 2020-09-14 2023-04-13 Arvinas Operations, Inc. Crystalline forms of a compound for the targeted degradation of estrogen receptor
JP2025512788A (ja) * 2022-03-25 2025-04-22 シェンチェン ファーマシン シーオー.,エルティーディー. Protac化合物の医薬組成物及びその使用

Also Published As

Publication number Publication date
MX2025014795A (es) 2026-01-07
WO2024258856A1 (fr) 2024-12-19
TW202500155A (zh) 2025-01-01
AU2024303588A1 (en) 2025-12-18
EP4724045A1 (fr) 2026-04-15
CN121311218A (zh) 2026-01-09
KR20260022394A (ko) 2026-02-19
JP2026522318A (ja) 2026-07-07

Similar Documents

Publication Publication Date Title
JP5835883B2 (ja) 被覆錠剤製剤
JP5801826B2 (ja) ダビガトランエテキシラートを含有する経口用医薬組成物
KR20150097792A (ko) 개선된 생체이용률을 갖는 약학 조성물
WO2012164578A1 (fr) Compositions et procédés de préparation de formulations de nilotinib à libération immédiate
JP7648698B2 (ja) 難溶性の塩基性薬剤を含有する医薬組成物
WO2015124995A1 (fr) Formes galéniques solides de rivaroxaban
EP3620156A1 (fr) Composition ayant une solubilité dans l'eau et une biodisponibilité améliorées
US20140319720A1 (en) Pharmaceutical compositions comprising rivaroxaban
KR101479824B1 (ko) 용출 안정성 제제
NZ760233A (en) Compositions and methods for treatment of abnormal cell growth
JP5635491B2 (ja) 固形医薬組成物
JP5769362B2 (ja) 圧縮製剤
TWI624275B (zh) 具有高含量菲索芬那定(fexofenadine)之固態單位及其製備方法
EP2540294A1 (fr) Préparation solide à libération prolongée pour usage oral
KR101171375B1 (ko) 난용성 약물을 함유하는 경구 제형
EP1959934A2 (fr) Comprime bicouche comprenant du telmisartan et un diuretique
US20130085145A1 (en) Imatinib mesilate pharmaceutical tablet
US20090030057A1 (en) Pharmaceutical composition of telmisartan
EP4724045A1 (fr) Formes posologiques orales solides d'agents de dégradation des récepteurs des ?strogènes
US11260055B2 (en) Oral pharmaceutical composition of lurasidone and preparation thereof
KR101944085B1 (ko) 발사르탄 함유 고형 경구제형 및 그 제조방법
CN112057427A (zh) 一种含有布鲁顿氏酪氨酸激酶抑制剂的口服固体片剂及其制备方法
EP4729048A1 (fr) Comprimés d'oxazépam à dispersion orale
WO2026019402A1 (fr) Composition pharmaceutique comprenant une nanosuspension de canagliflozine
CN116492305A (zh) 一种盐酸洛氟普啶片及其制备方法